Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 4 February 2026 - 5 February 2026

Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck shares rose 2.2% to $118.33 in after-hours trading Wednesday after new data showed its experimental cholesterol drug enlicitide cut LDL by up to 60% in a major trial. The company’s 2026 revenue forecast of $65.5–$67.0 billion missed Wall Street estimates, citing pressure from off-patent drugs and U.S. pricing. Keytruda sales reached $8.37 billion last quarter, while Gardasil revenue fell 34%.
5 February 2026
····
AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie shares fell 3.9% in after-hours trading Wednesday after quarterly results showed Rinvoq sales missed expectations at $2.37 billion. Skyrizi sales beat forecasts at $5.01 billion, while Humira revenue dropped 25.9% to $1.25 billion. The company projected 2026 adjusted earnings above estimates, but investors focused on challenges replacing Humira as biosimilar competition grows.
5 February 2026
·····
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie shares fell 2.5% to $219.98 Wednesday after Rinvoq sales missed forecasts, despite the company raising its 2026 profit outlook. Q4 adjusted earnings reached $2.71 per share on $16.618 billion revenue; Skyrizi sales rose 32.5%, while Humira dropped 25.9%. AbbVie announced a three-year Medicaid pact with the Trump administration and pledged $100 billion in U.S. investments.
4 February 2026
·····
Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson shares rose 1% to $235.50 Wednesday, bucking a broader market decline. RBC raised its price target to $255, citing strong financials despite ongoing talc litigation. New data showed ERLEADA cut prostate cancer death risk by 51% versus darolutamide. Investors await updates at the AF Symposium on Feb. 6 and a TD Cowen event on March 3.
4 February 2026
·····
Merck stock price rises today as MRK rallies on Keytruda strength despite soft 2026 outlook

Merck stock price rises today as MRK rallies on Keytruda strength despite soft 2026 outlook

Merck shares rose 2.8% to $119.11 by midday Wednesday after the company beat Q4 expectations, but projected 2026 revenue of $65.5–$67.0 billion, below analyst forecasts. Keytruda sales climbed 7% while Gardasil dropped 34% on weak China demand. The company cited a $2.5 billion hit from generic drugs and U.S. pricing pressure. Investors remain focused on Merck’s ability to offset declines in older products.
4 February 2026
·····
Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk shares fell 16% in Copenhagen after the company warned 2026 sales and profit may drop up to 13% due to falling U.S. drug prices and tougher competition. ADRs slid nearly 4% in New York. Novo plans a share buyback of up to 15 billion Danish crowns and named Jamey Millar as its new U.S. head. CEO Mike Doustdar said Wegovy price cuts have hit results but are meant to boost future demand.
4 February 2026
·····
Eli Lilly (LLY) stock price jumps 10% after 2026 outlook; pricing pressure and FDA decision in focus

Eli Lilly (LLY) stock price jumps 10% after 2026 outlook; pricing pressure and FDA decision in focus

Eli Lilly shares jumped 10% Wednesday after reporting a 43% rise in Q4 revenue to $19.3 billion, fueled by strong Mounjaro and Zepbound sales. The company forecast 2026 revenue of $80–83 billion and non-GAAP EPS of $33.50–$35.00. Investors remain focused on pricing pressure ahead of the FDA’s April decision on orforglipron.
4 February 2026
·····
Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook

Pfizer shares fell 3.4% to $25.77 in Wednesday’s premarket after Novo Nordisk warned of lower 2026 sales and price pressure in obesity drugs. Pfizer’s GLP-1 trial met its main goal, showing up to 12.3% mean weight loss at 28 weeks, but safety questions remain. The company reaffirmed 2026 guidance and reported $17.6 billion in Q4 revenue. Investors await more VESPER-3 data at the June 6 ADA meeting.
4 February 2026
····
Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly shares fell 0.5% to $998.50 in premarket trading Wednesday after a 4% drop Tuesday, following Novo Nordisk’s warning of up to a 13% drop in 2026 sales and profits. Novo cut prices and launched an oral Wegovy, while Lilly plans to cap higher-dose obesity drug prices at $399 per month for repeat cash buyers. Investors await Lilly’s Q4 results and comments on pricing and competition.
4 February 2026
····
Novo Nordisk stock price sinks nearly 18% as 2026 outlook jolts Wegovy trade

Novo Nordisk stock price sinks nearly 18% as 2026 outlook jolts Wegovy trade

Novo Nordisk shares fell about 18% in Copenhagen after the company warned of a possible 5–13% drop in 2026 sales and profit, citing U.S. price cuts and rising competition. The drugmaker faces pressure from cheaper copycat obesity drugs and a leadership change in its U.S. unit set for Feb. 5. U.S.-listed shares dropped 14.2% Tuesday.
4 February 2026
····
Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk warned adjusted sales and operating profit may fall 5% to 13% in 2026, citing U.S. price cuts and rising competition from Eli Lilly. Shares plunged 18% in early Copenhagen trading. CEO Mike Doustdar called the U.S. price reductions for Wegovy “painful.” Novo also flagged patent expiries and pressure from compounded GLP-1 drugs.
4 February 2026
·····
GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK shares rose 1.4% Wednesday morning after new CEO Luke Miels issued a 2026 outlook projecting slower sales growth and warning of possible weakness in vaccines and general medicines. The company reported 2025 sales up 7% to £32.67 billion and forecast 2026 turnover growth of 3% to 5%. Investors remain focused on GSK’s ability to manage looming HIV patent expirations.
4 February 2026
····
1 2 3 4 5 … 56

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop